Lattice Biologics logo

Lattice Biologics(OTC) LBLTF

Market CapN/AMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2016)-100%
5 Year-100%
1 Year+0%
1 Month+0%
$0.00
+0.00%
+0.00Today
Lattice Biologics last closing stock price
MetricPriceDate
Last closeUSD 0.002026-05-13
Lattice Biologics stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+0%USD 0.002026-03-31
1 month+0%USD 0.002026-03-31
3 month+0%USD 0.002025-12-03
Year to date+0%USD 0.002025-12-03
1 year+0%USD 0.002024-12-24
3 year-99%USD 0.002022-09-15
5 year-100%USD 0.052021-05-13
Since inception-100%USD 0.202016-02-10

Lattice Biologics Financials at a Glance

Market Cap

N/AMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$1.56M

Net Income (TTM)

-$922.85K

EPS (TTM)

$0.00

P/E Ratio

0.00

Dividend

$0.00

Beta (Volatility)

10.08 (High)

Price

$0.00

Volume

3,000

Open

$0.00

Previous Close

$0.00

Daily Range

$0.00 - $0.00

52-Week Range

$0.00 - $0.00

Estimated Earnings Date

Mar 3, 2026

LBLTF News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Lattice Biologics

Lattice Biologics Ltd. is a biotechnology firm dedicated to developing, manufacturing, and commercializing biological products for bone regeneration. The company’s innovative solutions are utilized globally in dental, spinal, and orthopedic applications.

Products and Services
  • AmnioBoost and AmnioBlast therapies for tissue regeneration
  • A diverse range of allografts for various medical applications
  • Products supporting spinal fusion, wound repair, and orthopedic surgeries
Growth Outlook
  • Focus on expanding product offerings in regenerative medicine
  • Potential for increased market share in orthopedic and dental sectors
  • Strategic partnerships may enhance distribution and innovation capabilities
Financial Highlights
  • Recent quarterly revenue of $287,653, showing growth potential
  • Trailing twelve months (TTM) gross profit margin at 41.4%
  • Operating cash flow improved, indicating better cash management
Lattice Biologics Ltd. operates in the medical devices industry, focusing on innovative solutions for bone regeneration. The company’s product line includes advanced therapies and allografts that cater to a wide range of medical needs, from spinal surgeries to wound healing. The recent quarterly revenue indicates a positive trend, suggesting potential growth in market demand. The TTM gross profit margin reflects the company's ability to manage costs effectively, while improvements in operating cash flow signal enhanced financial health. As the company continues to expand its offerings and explore strategic partnerships, it may position itself favorably within the competitive landscape of regenerative medicine.
AI Generated • Sep 28, 2026

Industry

Biotechnology

Headquarters

Belgrade, MT 59714, US

LBLTF Financials

Key Financial Metrics (TTM)

Gross Margin

41.44%

Operating Margin

-13.64%

Net Income Margin

-60.19%

Return on Equity

23.33%

Return on Capital

N/A

Return on Assets

-49.14%

Earnings Yield

N/A

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

N/AMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

0

Volume

3.00K

Avg. Volume

0

Financials (TTM)

Gross Profit

$444.55K

Operating Income

-$615.47K

EBITDA

$19.92K

Operating Cash Flow

-$132.01K

Capital Expenditure

-$567.79K

Free Cash Flow

-$699.80K

Cash & ST Invst.

$0.00

Total Debt

$0.00

Lattice Biologics Performance Analysis

Lattice Biologics sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q42020-09-3057.8%
Q12020-12-31-40.4%
Q22021-03-31-39.4%
Q32021-06-30-100.0%
Lattice Biologics sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q42020-09-3040.6%
Q12020-12-31-10.5%
Q22021-03-31-42.9%
Q32021-06-3093.3%

Revenue Growth Rate

Annual and quarterly growth comparison

Currently no data to display.

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Currently no data to display.

Quarterly Performance

Name
Q3 2021YOY CHG

Revenue

$0.00

-100.0%

Gross Profit

$0.00

-100.0%

Gross Margin

0.00%

N/A

Market Cap

N/AMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

N/A

N/A

Employees

0

N/A

Net Income

-$25.85K

+91.9%

EBITDA

$43.06K

+124.1%

Quarterly Fundamentals

Name
Q3 2021YOY CHG

Total Cash

$0.00

-100.0%

Total Debt

$0.00

-100.0%

Accounts Receivable

$0.00

-100.0%

Inventory

$0.00

-100.0%

Long Term Debt

$0.00

-100.0%

Short Term Debt

$0.00

-100.0%

Return on Assets

-49.14%

N/A

Return on Invested Capital

6.98%

N/A

Free Cash Flow

$2.13K

+102.3%

Operating Cash Flow

$2.13K

+102.3%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
BZYRBurzynski Research Institute, Inc.
$0.00+0.00%
DCTHDelcath Systems, Inc.
$15.95+0.60%
KLYGKelyniam Global, Inc.
$0.14+0.00%
NMXSNet Medical Xpress Solutions, Inc.
$0.00+0.00%

Trending Stocks

Symbol / CompanyPricePrice Chg
INTCIntel
$118.67+2.36%
BITOProShares Trust - ProShares Bitcoin ETF
$11.26+0.45%
NVDANvidia
$230.67+1.52%
SPCXSpace Exploration Technologies
$150.62+0.93%

Questions About LBLTF

What is the current price of Lattice Biologics?

Lattice Biologics is trading at $0.00 per share.

What is the 52-week range for Lattice Biologics?

Over the past 52 weeks, Lattice Biologics has traded between $0.00 and $0.00.

How much debt does Lattice Biologics have?

Lattice Biologics total debt is unavailable.

How much cash does Lattice Biologics have on hand?

Lattice Biologics does not have cash on hand data available.

What is Lattice Biologics’s dividend yield?

Lattice Biologics does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.